Compare Stocks: TEVA, JNJ, CVS, and NVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVS CVS Health	$96.80 -0.4%	$100.79	$69.51 ▼ $110.68	$124.32B	0.59	7.08 million shs	4.48 million shs
JNJ Johnson & Johnson	$275.12 -1.2%	$261.98	$173.33 ▼ $281.07	$670.99B	0.24	6.40 million shs	4.04 million shs
NVO Novo Nordisk A/S	$46.59 -1.9%	$47.93	$35.12 ▼ $64.16	$208.07B	0.74	11.12 million shs	6.21 million shs
TEVA Teva Pharmaceutical Industries	$36.36 -0.7%	$34.64	$18.21 ▼ $38.37	$42.67B	0.87	5.12 million shs	7.40 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVS CVS Health	-0.35%	+3.92%	-2.46%	+0.72%	+32.00%
JNJ Johnson & Johnson	-1.27%	+2.54%	+6.73%	+18.18%	+54.82%
NVO Novo Nordisk A/S	-1.81%	+2.19%	+4.75%	+8.54%	-17.91%
TEVA Teva Pharmaceutical Industries	-0.60%	-0.25%	+4.68%	+6.28%	+93.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVS CVS Health	$96.80 -0.4%	$100.79	$69.51 ▼ $110.68	$124.32B	0.59	7.08 million shs	4.48 million shs
JNJ Johnson & Johnson	$275.12 -1.2%	$261.98	$173.33 ▼ $281.07	$670.99B	0.24	6.40 million shs	4.04 million shs
NVO Novo Nordisk A/S	$46.59 -1.9%	$47.93	$35.12 ▼ $64.16	$208.07B	0.74	11.12 million shs	6.21 million shs
TEVA Teva Pharmaceutical Industries	$36.36 -0.7%	$34.64	$18.21 ▼ $38.37	$42.67B	0.87	5.12 million shs	7.40 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVS CVS Health	-0.35%	+3.92%	-2.46%	+0.72%	+32.00%
JNJ Johnson & Johnson	-1.27%	+2.54%	+6.73%	+18.18%	+54.82%
NVO Novo Nordisk A/S	-1.81%	+2.19%	+4.75%	+8.54%	-17.91%
TEVA Teva Pharmaceutical Industries	-0.60%	-0.25%	+4.68%	+6.28%	+93.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVS CVS Health	2.92	Moderate Buy	$106.83	10.37% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$272.83	-0.83% Downside
NVO Novo Nordisk A/S	2.16	Hold	$64.94	39.38% Upside
TEVA Teva Pharmaceutical Industries	2.90	Moderate Buy	$42.89	17.96% Upside

Current Analyst Ratings Breakdown

Latest TEVA, JNJ, CVS, and NVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $48.00
9/3/2026	CVS CVS Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$126.00 ➝ $118.00
9/2/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$280.00 ➝ $320.00
8/27/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
8/26/2026	CVS CVS Health	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/21/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/19/2026	CVS CVS Health	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $114.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	CVS CVS Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$111.00 ➝ $118.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/12/2026	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $42.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVS CVS Health	$402.07B	0.31	$14.82 per share	6.53	$62.47 per share	1.55
JNJ Johnson & Johnson	$94.19B	7.04	$13.95 per share	19.72	$35.26 per share	7.80
NVO Novo Nordisk A/S	$329.43B	0.63	$4.59 per share	10.14	$6.58 per share	7.08
TEVA Teva Pharmaceutical Industries	$17.26B	2.46	$3.70 per share	9.82	$6.66 per share	5.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVS CVS Health	$1.77B	$3.78	25.61	11.40	0.95	1.18%	13.12%	3.95%	11/4/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	31.88	21.49	2.66	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.39	13.62	1.60	35.36%	61.20%	21.49%	11/4/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	60.60	12.08	4.57	4.08%	32.64%	6.34%	11/4/2026 (Estimated)

Latest TEVA, JNJ, CVS, and NVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	CVS CVS Health	$1.87	$2.58	+$0.71	$2.31	$100.03 billion	$106.10 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVS CVS Health	$2.66	2.75%	+5.87%	70.37%	4 Years
JNJ Johnson & Johnson	$5.36	1.95%	+5.25%	62.11%	64 Years
NVO Novo Nordisk A/S	$0.82	1.76%	+21.74%	20.05%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest TEVA, JNJ, CVS, and NVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026
7/10/2026	CVS CVS Health	quarterly	$0.6650	2.49%	7/23/2026	7/23/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVS CVS Health	0.74	0.87	0.66
JNJ Johnson & Johnson	0.44	1.09	0.81
NVO Novo Nordisk A/S	0.59	0.79	0.56
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVS CVS Health	80.66%
JNJ Johnson & Johnson	69.55%
NVO Novo Nordisk A/S	11.54%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
CVS CVS Health	0.85%
JNJ Johnson & Johnson	0.16%
NVO Novo Nordisk A/S	0.07%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVS CVS Health	300,000	1.28 billion	1.27 billion	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

TEVA, JNJ, CVS, and NVO Headlines

Recent News About These Companies

Nykredit A S Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 5 at 5:11 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Analysts

September 5 at 4:28 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - Slideshow

September 4 at 7:08 PM | seekingalpha.com

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

September 4 at 3:49 PM | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $48.00 at UBS Group

September 4 at 2:41 PM | marketbeat.com

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

September 4 at 11:50 AM | financialpost.comF

Teva Pharmaceutical Industries Ltd. Upgraded to Investment-Grade by S&P Global Ratings

September 4 at 11:50 AM | quiverquant.comQ

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

September 4 at 11:30 AM | globenewswire.com

Russian forces strike major pharmaceutical warehouse twice in one day

September 4 at 8:56 AM | msn.com

Teva Advances NYSE Listing With ADS Exchange Plan

September 3 at 6:51 PM | tipranks.com

Outperforming Pharma Stock Still Has Upside Potential

September 3 at 5:55 PM | finance.yahoo.com

Outperforming Pharma Stock Still Has Upside Potential

September 3 at 2:29 PM | schaeffersresearch.com

TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

September 3 at 12:54 PM | finance.yahoo.com

TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

September 3 at 12:26 PM | zacks.com

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

September 2 at 8:12 PM | finance.yahoo.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript

September 2 at 5:00 PM | seekingalpha.com

Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study

September 2 at 3:11 PM | finance.yahoo.com

Teva’s mAb shows benefit in celiac disease study

September 2 at 3:11 PM | clinicaltrialsarena.comC

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

September 2 at 10:10 AM | rttnews.com

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

September 2 at 10:10 AM | finance.yahoo.com

Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

September 2 at 10:01 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TEVA, JNJ, CVS, and NVO Company Descriptions

CVS Health NYSE:CVS

$96.80 -0.40 (-0.41%)

As of 09/4/2026 03:58 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Johnson & Johnson NYSE:JNJ

$275.12 -3.31 (-1.19%)

As of 09/4/2026 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novo Nordisk A/S NYSE:NVO

$46.59 -0.92 (-1.94%)

As of 09/4/2026 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Teva Pharmaceutical Industries NYSE:TEVA

$36.36 -0.26 (-0.71%)

As of 09/4/2026 03:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, JNJ, CVS, and NVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, JNJ, CVS, and NVO Earnings

Compare Dividends

Latest TEVA, JNJ, CVS, and NVO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, JNJ, CVS, and NVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TEVA, JNJ, CVS, and NVO Company Descriptions

CVS Health NYSE:CVS

Johnson & Johnson NYSE:JNJ

Novo Nordisk A/S NYSE:NVO

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools